Does Surface Tell us About the Invasive Front in Colorectal Cancer (CRC1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02002299|
Recruitment Status : Unknown
Verified July 2013 by Zealand University Hospital.
Recruitment status was: Recruiting
First Posted : December 5, 2013
Last Update Posted : December 5, 2013
|Condition or disease|
Timetable: From 1 August 2013 to 31 July 2014.
Organisational arrangements: The project is deleted from the pathology department, Roskilde Hospital, and surgical department, Roskilde Hospital.
inclusion criteria All colorectal surgical specimens having cancer were the patient did not receive neoadjuvant treatment received in the pathology department in accordance with current guidelines with the cutting of the tumor area in parallel slices and photographed, so there is macroscopic photo documentation.
Microscopic tumors classified as adenocarcinoma of glandular type, mucinous adenocarcinoma, signet ring cell carcinoma.
When the specimens is received at the department of pathology and is included in the study the pathologist report is registered in a local database.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||150 participants|
|Target Follow-Up Duration:||14 Days|
|Official Title:||Prospective Study of Colorectal Cancer Comparing the Surface With the Invasive Front|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||August 2014|
|Estimated Study Completion Date :||August 2014|
- invasive front growth pattern [ Time Frame: The histopathological study for one specimens takes one week at average, results will be published shortly after july 2014 (one year after start) ]
Microscopic divided tumors after growth pattern at the invasive front (tumor-bottom), rated on average, there is immunohistochemical stained for pancytokeratin. A points 1-4 described by Franzen et al (2008) used: tumor bottom is regular and smooth (score 1), tumor-bottom is irregular with large cell clusters (score 2), tumor-bottom is irregular with large and small clusters (score 3) and tumor-bottom consists almost entirely of smaller clusters (score 4).
It is also noted whether there is a tumor budding or not. Tumor budding is a histological phenomenon that reflect loss of adhesion between tumor cells in the stroma of the invasive front of colorectal cancers. It is present if more than five groups containing 1-4 cancer cells each, within a microscopic area on x20 (Uneo et al (x25), 2002 and Mitrovic et al (x20), 2012).
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02002299
|Contact: Susanne Eiholm, MDemail@example.com|
|Contact: Henrik Ovesen, MDfirstname.lastname@example.org|
|Department of Pathology,||Recruiting|
|Roskilde, Denmark, 4000|
|Contact: Susanne Eiholm, MD +4547325943 email@example.com|
|Contact: Henrik Ovesen, MD +4547323004 firstname.lastname@example.org|
|Principal Investigator: Susanne Eiholm, MD|
|Principal Investigator:||Susanne Eiholm, MD||Department of Pathology, Roskilde Hospital, Denmark|